ORIGINAL ARTICLE

Risk score of contrast-induced nephropathy in patients after percutaneous coronary intervention

Morlim Limbong , Yan Herry, Pipin Ardhianto, Suhartono Suhartono

Morlim Limbong
Resident in Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Diponegoro-Dr. Kariadi Hospital, Semarang, Indonesia. Email: [email protected]

Yan Herry
Departemen of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Diponegoro-Dr. Kariadi Hospital, Semarang, Indonesia

Pipin Ardhianto
Departemen of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Diponegoro-Dr. Kariadi Hospital, Semarang, Indonesia

Suhartono Suhartono
Public Health Department, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
Online First: April 30, 2021 | Cite this Article
Limbong, M., Herry, Y., Ardhianto, P., Suhartono, S. 2021. Risk score of contrast-induced nephropathy in patients after percutaneous coronary intervention. Bali Medical Journal 10(1): 400-404. DOI:10.15562/bmj.v10i1.2222


Background: Contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) is still an issue in modern revascularization era. Recent risk stratification model used creatinine as biomarker which has some limitations. Increased ≥ 10 % of Cystatin-C after PCI has proven to be one of the earliest and accurate CIN after PCI biomarkers. The study aims to develop risk score based on predictors of contrast-induced nephropathy in patients after PCI with Cystatin-C as biomarker

Methods: A prospective cohort study of 129 patients after PCI at Dr. Kariadi General Hospital Semarang. Predictor analysis was carried out using bivariate chi-square test and multivariate logistic regression. The independent predictors obtained were then used as risk score variables. The Hosmer and Lemeshow calibration test and AUC ROC analysis for discrimination test tested the quality of the risk score.

Results: There were 3 independent predictors used as the risk score variables: Hypotension (score 1), anemia (score 1), creatinine baseline >1.5 mg/dl (score 1). Patients with total score ≥1 have higher risk to have CIN after PCI. The risk score had a good quality with the Hosmer and Lemeshow calibration test > 0.05 and relative modest discrimination ROC AUC 0.700 (95% IK 0.585-0.815;  p=0.001).

Conclusions: A risk score for risk stratification CIN after PCI has been created. The score has  good calibration and modest discrimination in predicting the risk of CIN after PCI.

References

Jin B, Chul K, Soo B, Ho J, Beck K, Kim H, et al. Effect of N -Acetylcysteine on cystatin C-Based renaL function after Elective coronary angiography (ENABLE Study): A prospective , randomized trial. Int J Cardiol. 2010;138:239–245.

Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. 2006;69:S11–S15.

Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli hospitalized patients: Incidence, risk factors, length of stay and mortality. Isr Med Assoc J. 2009;11:460–464.

McCullough PA. Radiocontrast-Induced Acute Kidney Injury. In: Nephron Physiol. 2008, pp. 61–72.

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;12:1–96.

Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: Systematic review. BMJ. 2015;351:h4395.

Briguori C, Quintavalle C, Donnarumma E, Condorelli G. Novel biomarkers for contrast-induced acute kidney injury. Biomed Res Int. 2014;2014:568738.

Shukla AN, Juneja M, Patel H, Shah KH, Konat A, Thakkar BM, et al. Diagnostic accuracy of serum cystatin C for early recognition of contrast induced nephropathy in Western Indians undergoing cardiac catheterization. Indian Heart J. 2017;69:311–315.

Sato A, Hoshi T, Kakefuda Y, Aonuma K. Effect of the Mehran risk score for the prediction of clinical outcomes after percutaneous coronary intervention. J Cardiol. 2015;66:417–422.

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399.

Li WH, Li DY, Han F, Xu T Da, Zhang YB, Zhu H. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions. Int Urol Nephrol. 2013;45:1065–1070.

Müller V, Häberle L, Heinrich MC, Bautz W, Uder M. Nephrotoxicity of Iso-osmolar Iodixanol Compared with Nonionic Low-osmolar Contrast Media: Meta-analysis of Randomized Controlled Trials. Radiology. 2008;250:68–86.

Zanoli L, Blanco J, Capodanno D, Rastelli S, Castellino P, Tamburino C, et al. Reference Renal Artery Diameter Is a Stronger Predictor of Contrast-Induced Nephropathy than Chronic Kidney Disease in Patients with High Cardiovascular Risk. Nephron Extra. 2011;1:38–44.

Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16 Suppl 1:S22-30.

Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70:199–203.

Thadhani R, Bonventre J V., Han WK, Abichandani R, Bailly V. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62:237–244.

Pan HC, Wu XH, Wan QL, Liu And BH, Wu XS. Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention. Exp Biol Med (Maywood). 2018;243(12):970-975.

Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300–305.

Tan H, Liu K, Zhang Q, Zhang X, Han X. Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials. PLoS One. 2018;13:e0194330.

Islam SMS, Chen J, Tan N, Wang K, Guo X, Chen S, et al. Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure. Ther Clin Risk Manag. 2017;13:887–895.

Shacham Y, Leshem-Rubinow E, Gal-Oz A et al. Association of left ventricular function and acute kidney injury among ST-elevation myocardial infarction patients treated by primary percutaneous interventionNo Title. Am J Cardiol 2015;115:293–297.

Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, et al. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol 2010;42:1049–1054.

Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515–1519.

Ningrum NR, Yuniadi Y. Contrast Induced Nephropathy Tinjauan Pustaka Contrast Induced Nephropathy. 2009;30:71–79.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0